DMA Diamedica Therapeutics

DiaMedica (TSX VENTURE:DMA), a clinical stage biopharmaceutical company, today
announced that the final Type 2 diabetic patient has been enrolled in the single
ascending dose (SAD) portion of the DM199 Phase I/II clinical study. The
randomized, placebo-controlled, double-blinded study is evaluating three dose
levels in each Type 2 diabetic patient. 


"Completion of the enrollment of Type 2 Diabetic patients into the SAD portion
of the Phase I/II clinical study is an important milestone in our DM199
development pathway," said Rick Pauls, Chairman and CEO at DiaMedica. "We are
looking forward to the top line results from this study which will be available
in Q3 2013."


The primary objective of the SAD portion of the ongoing Phase I/II clinical
study is to evaluate acute safety, tolerability and pharmacokinetic properties
for the first time in Type 2 diabetic patients, as well as the effect of DM199
on improving glucose control.


About DiaMedica 

DiaMedica Inc. is a publicly traded (TSX VENTURE:DMA) clinical stage
biopharmaceutical company focused on the discovery and development of novel
therapies to treat diabetes and the complications associated with diabetes.
DiaMedica's lead clinical stage compound, DM199, is a recombinant human protein
that represents a novel approach to treating Type 1 and Type 2 diabetes.
DiaMedica is also developing a novel monoclonal antibody, DM-204 for the
treatment of Type 2 diabetes, which is in preclinical development. 


The Company is listed on the TSX Venture Exchange in Canada under the trading
symbol 'DMA'.


FORWARD-LOOKING STATEMENTS 

The statements made in this press release that are not historical facts contain
forward-looking information that involves risk and uncertainties. All
statements, other than statements of historical facts, which address DiaMedica's
expectations, should be considered forward-looking statements. Such statements
are based on management's exercise of business judgment as well as assumptions
made by and information currently available to management. When used in this
document, the words "may", "will", "anticipate", "believe", "estimate",
"expect", "intend" and words of similar import, are intended to identify any
forward-looking statements. You should not place undue reliance on these
forward-looking statements. These statements reflect a current view of future
events and are subject to certain risks and uncertainties as contained in the
Corporation's filings with Canadian securities regulatory authorities. Should
one or more of these risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results could differ materially from those
anticipated in these forward-looking statements. The Corporation undertakes no
obligation, and does not intend, to update, revise or otherwise publicly release
any revisions to these forward-looking statements to reflect events or
circumstances after the date hereof, or to reflect the occurrence of any
unanticipated events. Although management believes that expectations are based
on reasonable assumptions, no assurance can be given that these expectations
will materialize.


FOR FURTHER INFORMATION PLEASE CONTACT: 
DiaMedica Inc.
Rick Pauls
Chairman & CEO
763-710-4455
info@diamedica.com

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jun 2024 to Jul 2024

DiaMedica Inc. (TSXV:DMA)
Historical Stock Chart
From Jul 2023 to Jul 2024